Novo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugs
Novo Nordisk is teaming up with Swiss start-up Eracal Therapeutics, which is specialized in discovering new drugs from a zebrafish larvae platform. The firms will develop treatments targeted at food intake and other factors associated with obesity.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersem
A new research collaboration between Novo Nordisk and a start-up from Switzerland, Eracal Therapeutics, has seen the light of day, a company press release announces.